Search results for "Clear cell renal cell carcinoma"

DHH is an independent prognosticator of oncologic outcome of clear cell renal cell carcinoma.

2014

Aberrant HH signaling has proved important in the pathogenesis of several solid cancers. Limited in vitro analyses suggested an oncogenic role for HH in renal cell carcinoma. In this explorative study we sought to validate aberrant HH expression in patients with renal cell carcinoma.A tissue microarray was constructed from 140 radical nephrectomy specimens of patients with clear cell renal cell carcinoma. We performed immunohistochemistry for Ki67 and HH pathway biomarkers, including PTCH1, Smo, SHH, IHH, DHH, Gli1, Gli2 and Gli3. Staining intensity was measured by automated image processing and related to tumor stage and grade. The impact of biomarker expression on cancer specific survival…

Clinical and genomic alternations predictive of response to sunitinib in patients with advanced renal cell carcinoma.

2016

e16109Background: Sunitinib is a 1st-line therapy for clear cell Renal Cell Carcinoma (ccRCC); however, 20-30% of tumors show primary resistant disease with progression as the best response. This s...

2017

Renal cell carcinoma (RCC) comprises a heterogenous group of tumors. Traditionally, papillary RCC (pRCC) is associated with a favorable outcome compared to clear cell RCC (ccRCC), while other series report equivalent or worse prognosis. In this paper we comparatively evaluate outcome of pRCC versus ccRCC in two large multi-institutional databases (cohort study), including distribution of pRCC subtypes 1 and 2. Retrospective data of 1,943 surgically treated pRCC patients from 17 European/ North American centers between 1984-2015 were compared to 5,600 ccRCC patients from a database comprising 11 European/ North American centers (1984-2011). Median follow-up was 64.6 months. Differences betwe…

Classification of Renal Cell Carcinoma Based on Morphologic and Cytogenetic Correlations

1995

Typing or classification of renal cell carcinomas — a term introduced by Murphy and Mostofi in 1965 (1) — has been a debatable field since Grawitz (2) introduced the term hypernephroma in 1883. Grawitz postulated a hypernephrogenic origin of renal cancers, whose cells exhibit a light cytoplasm. During recent decades it has become customary to view renal cell carcinoma as a complex entity. Despite support for this idea by the World Health Organization (3) a morphological subtyping of renal cell carcinoma has not been recognized until recently. In 1986 Thoenes et al. (4) proposed a new pathomorphological subtyping of epithelial renal cell tumors, renal cell carcinoma (RCC) and adenoma (RCA), …

Systematic Comparative Protein Expression Profiling of Clear Cell Renal Cell Carcinoma

2009

Proteome-based technologies represent powerful tools for the analysis of protein expression profiles, including the identification of potential cancer candidate biomarkers. Thus, here we provide a comprehensive protein expression map for clear cell renal cell carcinoma established by systematic comparative two-dimensional gel electrophoresis-based protein expression profiling of 16 paired tissue systems comprising clear cell renal cell carcinoma lesions and corresponding tumor-adjacent renal epithelium using overlapping narrow pH gradients. This approach led to the mapping of 348 distinct spots corresponding to 248 different protein identities. By implementing restriction criteria concernin…

Efecto de la radiación ionizante persistente a bajas dosis en la angiogénesis del carcinoma renal de células claras : estudio morfométrico comparativ…

2013

La angiogénesis en el carcinoma de células renales claras (ccRCC) es un proceso influenciado por sustancias producidas en su mayoría por el tumor en respuesta a una reestructuración vascular necesaria en su etapa de crecimiento y metástasis. La exposición persistente a bajas dosis de radiación ionizante (CPLDIR) ha sido asociada a modificaciones nucleares que estimulan la proliferación celular neoplásica. Sus efectos en el proceso de neovascularización de los ccRCC han sido poco estudiados. Métodos: Estudiamos a través de un estudio morfométrico semiautomático e inmunohistoquímico, la densidad microvascular (MVD) y la expresión de factores angiogénicos en 124 pacientes con ccRCC de regiones…

VHL gēna mutācijas gaišo šūnu nieru karcinomas gadījumā

2019

Nieru šūnu karcinoma ir sestais biežāk diagnosticētais audzējs no visām onkoloģiskajām diagnozēm pasaulē. Gaišo šūnu nieru karcinoma ir 65-70% no visiem saslimšanas gadījumiem ar nieru audzējiem. Izmaiņas von Hippel-Lindau (VHL) gēnā, kurš ir visbiežāk mutētais gēns gaišo šūnu nieru karcinomas gadījumā, tiek salīdzinātas starp in vitro audzētām cilvēku nieru proksimālo kanāliņu epitēlija šūnām un gaišo šūnu nieru karcinomas šūnu līnijām un primārajām šunām, kuras iegūtas no gaišo šūnu nieru karcinomas pacientu audiem un blakus esošiem veselajiem audiem. Darba rezultātā tika konstatēts viena nukleotīda polimorfisms pacientu gaišo šūnu nieru karcinomas audos un veselajos audos no VHL gēna izo…

Is the Complement Protein C1q a Pro- or Anti-tumorigenic Factor? Bioinformatics Analysis Involving Human Carcinomas

2019

C1q is the first subcomponent of the classical pathway of the complement system and belongs to the C1q/Tumor Necrosis Factor superfamily. C1q can perform a diverse range of immune and non-immune functions in a complement-dependent as well as -independent manner. Being a pattern recognition molecule of the innate immunity, C1q can recognize a number of self, non-self and altered-self ligands and bring about effector mechanisms designed to clear pathogens via opsonisation and inflammatory response. C1q is locally synthesized by macrophages and dendritic cells, and thus, can get involved in a range of biological processes, such as angiogenesis and tissue remodeling, immune modulation, and immu…